News
It could be the first new treatment for gonorrhea in 30 years. It could be the first new treatment for the infection in 30 ...
GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and ...
A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...
A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...
A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...
GSK's Blujepa (gepotidacin) becomes the first in a new class of oral antibiotics to treat uncomplicated UTIs (also known as uUTIs) in almost 30 years, taking aim at infection-causing bacteria ...
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...
GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results